Tom Watson BS

Tom Watson was an Executive Vice President of Early Access Programs at Bionical. For the last 6 years, Tom has partnered with pharma and biotech companies to design their strategy for Pre-approval Access and develop global programs, allowing patients to gain access to treatments that would otherwise be unavailable to them whilst supporting traditional development pathways. Within this time, Tom has been involved in setting up and running over 200 global programs all tailored to the needs of the asset and the company. His previous roles as Executive Director for TW Consulting Group and Head of U.S. Business Development for Clinigen Group has provided a platform to help patients around the world whilst developing thinking and strategy for many of the Top 20 Pharma companies in this important area.

Tom now heads up the Early Access Programs business at Bionical Group. Previously to working in this space, Tom spent 14 years within the pharmaceutical industry fulfilling a range of leadership roles including Head of Marketing for a multinational pharma company. Within this time, he led a wide range of global pre-launch and launch activities for treatments addressing areas of high unmet medical need. Tom is a member of the New York University School of Medicine Working Group on Compassionate Use and Pre- Approval Access. He is deeply committed to helping companies with promising medicines in development and the patients they serve.